Join Growin Stock Community!

ABC-KY6598.TW Overview

TW StockBiotech. & Medical
(No presentation for 6598)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ABC-KY（6598）Overall Performance

ABC-KY（6598）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ABC-KY（6598） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ABC-KY（6598）Key Information

ABC-KY（6598）Profile

Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex diagnostic testing products for the In-Vitro diagnostics market. The company's products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. In addition, It develops assays, such as BioCode SARS-CoV-2 Assay, a high volume automated nucleic acid multiplex assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; BioCode Respiratory Pathogen Panels, which simultaneously detects and differentiates the presence of 17 respiratory pathogens in nasopharyngeal swabs; BioCode gastrointestinal (GI) pathogen panels for common GI pathogens, including viruses, bacteria, and parasites that cause infectious diarrhea; and MDx assays pipeline for various molecular tests. Further, the company offers fungal pathogen analyte specific reagents; human cytokine/chemokine multiplex kits to identify relevant biomarkers; mouse premixed multiplex kits and custom panels for enhancing flexibility in experimental design allowing the user to pick and choose their own analytes panel; and rat, monkey, canine, and non-human primate cytokine/chemokine multiplex kits. Additionally, the company provides BMB, calibration beads, and coupling kits for various bioassay applications; ELISA, a tool for the quantitative measurement of drug/protein/antibody levels in biological samples comprising cell lysate or serum; and various assay development services. Applied BioCode Corporation is based in Santa Fe Springs, California.

ABC-KY（6598）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.02
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5.88
PB Ratio
3.80
Price-to-FCF
25.20
METRIC
VALUE
vs. INDUSTRY
Gross Margin
58.12%
Net Margin
-46.83%
Revenue Growth (YoY)
14.85%
Profit Growth (YoY)
-1.41%
3-Year Revenue Growth
4.45%
3-Year Profit Growth
5.72%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.02
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5.88
PB Ratio
3.80
Price-to-FCF
25.20
Gross Margin
58.12%
Net Margin
-46.83%
Revenue Growth (YoY)
14.85%
Profit Growth (YoY)
-1.41%
3-Year Revenue Growth
4.45%
3-Year Profit Growth
5.72%
default symbol

6598

ABC-KY

25.40D

-0.59%

(-0.01)

  • When is 6598's latest earnings report released?

    The most recent financial report for ABC-KY (6598) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6598's short-term business performance and financial health. For the latest updates on 6598's earnings releases, visit this page regularly.

  • What is the operating profit of 6598?

    According to the latest financial report, ABC-KY (6598) reported an Operating Profit of -38.72M with an Operating Margin of -31.52% this period, representing a growth of 51.16% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6598's revenue growth?

    In the latest financial report, ABC-KY (6598) announced revenue of 122.82M, with a Year-Over-Year growth rate of 63.87%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6598 have?

    At the end of the period, ABC-KY (6598) held Total Cash and Cash Equivalents of 517.62M, accounting for 0.5 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6598 go with three margins increasing?

    In the latest report, ABC-KY (6598) did not achieve the “three margins increasing” benchmark, with a gross margin of 63.41%%, operating margin of -31.52%%, and net margin of -27.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6598's profit trajectory and future growth potential.

  • Is 6598's EPS continuing to grow?

    According to the past four quarterly reports, ABC-KY (6598)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.33. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6598?

    ABC-KY (6598)'s Free Cash Flow (FCF) for the period is 18.34M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 104.61% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.